Blogger Facebook Twitter You Tube RSS

Recombinant Human Parainfluenza Type-3 Virus for High Throughput Antiviral and Viral Infection Assays

Human parainfluenza type 3 (HPIV-3) is all too common among children, manifesting in multiple different severities and causing pneumonia, bronchiolitis, and croup. According to the CDC, 50% of children in the US are infected during the first year of life and almost all are infected by 6 years of age. Immunocompromised and elderly patients also have elevated risk for infection with HPIV-3. The development of a vaccine against HPIV-3 has not been successful up to date. Utah State University seeks a licensee for commercialization of technology relating to an EGFP expressing, recombinant HPIV-3 (rHPIV-3) that provides for high throughput assays of, and screening for, antiviral compounds active against HPIV-3.
Features and Benefits
  • High throughput antiviral screening of HPIV-3 antiviral compounds
  • In-vivo drug screening
  • In-vitro drug screening
  • Measuring of viral replication
  • Identifying locations of viral replication
  • Level of EGFP expression is directly related to rHPIV-3 replication
  • A wide range of EGFP fluorescence can be detected
  • Reduced processing time and labor for an antiviral assays
  • The detection limits of the assay are sensitive and robust
  • Detects an increase or decrease in rHPIV-3 replication
  • Allows real-time quantification and detection of rHPIV-3 replication in vitro
This technology provides constructs and methods to rescue an infectious, recombinant HPIV-3 virus, which is useful in conducting high-throughput screens of anti-HPIV-3 compounds. The enhanced green fluorescent protein (EGFP) gene has been inserted into the human parainfluenza virus type 3 (HPIV-3) antigenome and a recombinant, infectious virus has been rescued. Maximum EGFP expression levels, measured by fluorescence, are seen at day 3. A three-day, endpoint EGFP-based antiviral assay and a seven-day, endpoint neutral red based antiviral assay were run in parallel to establish antiviral sensitivity profiles of 23 compounds based on selective index (SI) values. Using an SI threshold of 10, the EGFP-based antiviral assay had a sensitivity of 100% and a specificity of 54%.
Development Stage
The EGFP expressing, recombinant human parainfluenza virus has been demonstrated to work in proof-of-concept experiments for use in primary, high-throughput screens for anti-viral compounds. This technology is currently available under non-exclusive terms.
U.S. Patent Pending
Joe Christison
Senior Commercialization Associate
Life Sciences
(435) 797-9614
Reference: W04023 (v2)